IIT2025-03-YANG-LIFT-HCC

NCT07489976 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Hepato Cellular Carcinoma

Interventions

DRUG: STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)

Sponsor

Ju Dong Yang